Medicus Pharma secures $8M non-dilutive debenture from Yorkville; net proceeds $5.7M

Medicus Pharma Ltd.

$8M principal, 8% interest, matures Sept 2026; monthly installments of $650k plus accrued interest.
Refinances ~$1.7M existing debt; net proceeds ~$5.7M after discount, fees, and debt repayment.
Proceeds to accelerate Teverelix (GnRH Antagonist) for AURr and high CV risk prostate cancer (~$6B market).
Optional redemption at any time at face value plus interest; Yorkville may force redemption from equity financings (excluding SEPA).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.